Twist Bioscience Corporation Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Twist Bioscience Corporation stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $3.79M, a 107.38% increase year-over-year.
- Twist Bioscience Corporation stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.79M, a 132.04% increase year-over-year.
- Twist Bioscience Corporation stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $300.00K, a 89.83% decline year-over-year.
- Twist Bioscience Corporation stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $3.79M, a 97.81% increase year-over-year.
- Twist Bioscience Corporation stock issued during period, value, stock options exercised for fiscal 2025 was $9.34M, a 31.59% increase from fiscal 2024.
- Twist Bioscience Corporation stock issued during period, value, stock options exercised for fiscal 2024 was $7.10M, a 414.87% increase from fiscal 2023.
- Twist Bioscience Corporation stock issued during period, value, stock options exercised for fiscal 2023 was $1.38M, a 76.83% decline from fiscal 2022.
- Twist Bioscience Corporation stock issued during period, value, stock options exercised for fiscal 2022 was $5.95M, a 58.87% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $3.79M 10-Q · filed 2026-08-03 | $9.67M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $1.79M 10-Q · filed 2026-05-04 | $7.71M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $300.00K 10-Q/A · filed 2026-02-26 | $6.69M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-09-30 | $3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $9.34M 10-K · filed 2025-11-17 |
| 2025-06-30 | $1.83M 10-Q · filed 2026-08-03 | $7.47M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $771.00K 10-Q · filed 2026-05-04 | $8.55M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $2.95M 10-Q/A · filed 2026-02-26 | $9.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-09-30 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $7.10M 10-K · filed 2025-11-17 |
| 2024-06-30 | $2.92M 10-Q · filed 2025-08-04 | $5.37M derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-03-31 | $1.32M 10-Q · filed 2025-05-05 | $2.79M derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-12-31 | $951.00K 10-Q · filed 2025-02-03 | $1.73M derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-09-30 | $184.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | $1.38M 10-K · filed 2025-11-17 |
| 2023-06-30 | $342.00K 10-Q · filed 2024-08-02 | $2.45M derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-03-31 | $250.00K 10-Q · filed 2024-05-02 | $2.87M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-12-31 | $603.00K 10-Q · filed 2024-02-02 | $3.52M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-09-30 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-18 | $5.95M 10-K · filed 2024-11-18 |
| 2022-06-30 | $766.00K 10-Q · filed 2023-08-07 | $7.42M derived: sum of 4 quarters · filed 2023-11-21 |
| 2022-03-31 | $896.00K 10-Q · filed 2023-05-08 | $9.27M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-12-31 | $3.04M 10-Q · filed 2023-02-07 | $11.44M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-09-30 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | $14.47M 10-K · filed 2023-11-21 |
| 2021-06-30 | $2.62M 10-Q · filed 2022-08-08 | $17.29M derived: sum of 4 quarters · filed 2023-06-05 |
| 2021-03-31 | $3.07M 10-Q · filed 2022-05-06 | $16.57M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-12-31 | $6.07M 10-Q · filed 2022-02-09 | $14.89M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-09-30 | $5.53M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | $10.54M 10-K/A · filed 2023-06-05 |
| 2020-06-30 | $1.90M 10-Q · filed 2021-08-09 | $6.14M derived: sum of 4 quarters · filed 2021-11-23 |
| 2020-03-31 | $1.39M 10-Q · filed 2021-05-07 | $5.13M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-12-31 | $1.72M 10-Q · filed 2021-02-09 | $3.81M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-09-30 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-23 | $2.26M 10-K · filed 2021-11-23 |
| 2019-06-30 | $899.00K 10-Q · filed 2020-08-12 | $1.22M derived: sum of 4 quarters · filed 2020-11-27 |
| 2019-03-31 | $66.00K 10-Q · filed 2020-05-13 | $293.00K derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-12-31 | $166.00K 10-Q · filed 2020-02-10 | $334.00K derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-09-30 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-27 | $215.00K 10-K · filed 2020-11-27 |
| 2018-06-30 | -$31.00K 10-Q · filed 2019-08-09 | |
| 2018-03-31 | $107.00K 10-Q · filed 2019-05-02 | |
| 2017-12-31 | $47.00K 10-Q · filed 2019-02-11 | |
| 2017-09-30 | $162.00K 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |